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The yeast Malassezia furfur belongs to the normal
cutaneous ¯ora, but is also a triggering allergen that
can contribute to atopic dermatitis. To illuminate
the effect of circulating allergen-speci®c T cells in
atopic dermatitis, the peripheral mononuclear cell
response was correlated with the in vivo skin prick
test and atopy patch test reactivity to M. furfur. None
of 16 healthy controls showed any positive in vivo
reaction. The 40 atopic dermatitis patients, of whom
18 had serum IgE reactivity to M. furfur, were sub-
divided according to their in vivo reaction to M. furfur
extract into three groups: skin prick test positive/
atopy patch test positive (n = 12), skin prick test
positive/atopy patch test negative (n = 12), and skin
prick test negative/atopy patch test negative
(n = 16). The skin prick test positive/atopy patch
test positive and the skin prick test positive/atopy
patch test negative groups had a signi®cantly higher
peripheral mononuclear cell stimulation index than
the healthy controls. Interestingly, the stimulation
index values in the skin prick test positive/atopy
patch test positive group were signi®cantly higher
than in the skin prick test positive/atopy patch test
negative group. In the M. furfur skin prick test posi-
tive atopic dermatitis patients (n = 24) a correlation
was found between stimulation index and the M. fur-
fur atopy patch test reactions, but not between
stimulation index and M. furfur-speci®c serum IgE
levels. Skin prick test positive and/or atopy patch
test positive reactions to the recombinant M. furfur
allergens rMal f 1, rMal f 5, and rMal f 6 were
observed in 7, 14, and 16 of the 40 atopic dermatitis
patients, respectively. Further, there was a correl-
ation between production of the T helper 2-related
cytokines interleukins 4, 5, and 13 and stimulation
index to M. furfur extract, but not between the T
helper 1-related interferon-g and stimulation index to
M. furfur extract. Our data strongly suggest a rela-
tionship between circulating speci®c T cells with a T
helper 2-like cytokine pro®le and positive atopy
patch test reactions. Key words: allergens/cytokines/
ELISPOT/peripheral mononuclear cell proliferation/recom-
binant proteins. J Invest Dermatol 118:1044±1051, 2002
A
topic dermatitis (AD) is a chronic multifactoral
in¯ammatory skin disease, which has increased in
prevalence during the past few decades (Rajka, 1989;
ISAAC, 1998). Its pathogenesis is still not fully
understood. As approximately 80% of AD patients
show immediate-type skin reactions to environmental allergens
together with elevated serum IgE levels (OÈ hman and Johansson,
1974; Werfel and Kapp, 1998), it is assumed that allergens are
involved in maintenance of the disease. T helper (Th) cells are
thought to play an important part in the pathogenesis of AD.
Allergen-speci®c T cells cloned from acute AD lesional skin show a
Th2/Th0-like cytokine pro®le (van der Heijden et al, 1991;
Tengvall et al, 1996), whereas the in situ expression of interleukin
(IL)-4 in chronic AD lesions is accompanied by expression of
interferon (IFN)-g (Grewe et al, 1994; Hamid et al, 1994),
suggesting an involvement also of Th1 cytokines in the chronic
phase.
The yeast Malassezia furfur, earlier denoted Pityrosporum orbiculare
or P. ovale, belongs to the normal cutaneous ¯ora but is also
considered to be one of the triggering allergens that can contribute
to AD (Faergemann, 1999). A number of IgE-binding components
have been found in Malassezia (Zargari et al, 1994; Lintu et al,
1997). The genes for nine Malassezia allergens, Mal f 1±9, have
hitherto been identi®ed and cloned (Schmidt et al, 1997; Yasueda et
al, 1998; Lindborg et al, 1999; Onishi et al, 1999; Rasool et al,
2000).
Peripheral blood mononuclear cells (PBMC) from AD patients
with IgE reactivity to Malassezia show elevated proliferation in
response to in vitro stimulation with M. furfur extract (Rokugo et al,
1990; Tengvall Linder et al, 1996, 1998; Savolainen et al, 2001) and
also respond with a Th2-like cytokine pro®le (Tengvall Linder et al,
1996, 1998; Savolainen et al, 2001). No correlation, however, has
been demonstrated between speci®c serum IgE levels and PBMC
proliferation (Tengvall Linder et al, 1998, 2000).
The atopy patch test (APT) reaction, an eczematous skin
reaction induced by application of aeroallergens on nonlesional skin
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of AD patients, was ®rst described Mitchell et al (1982) and has
thereafter been evaluated in many studies (reviewed in TaõÈeb and
Ducombs, 1996). The presence of IgE on epidermal Langerhans
cells correlates with positive APT reactions (Mudde et al, 1990;
Langeveld-Wildschut et al, 2000). These reactions are similar to
those in acute AD lesions in terms of in®ltrating cells and their
phenotype, as examined by immunohistochemical techniques
(Langeveld-Wildschut et al, 1996; Tengvall Linder et al, 2000).
Positive APT reaction to M. furfur has been reported in 64% of the
AD patients investigated after chamber scari®cation (Rokugo et al,
1990), 13% when tested on intact skin (Kieffer et al, 1990), and 53%
on tape-stripped skin (Tengvall Linder et al, 2000).
The present aim was to compare the in vitro PBMC response
with in vivo skin prick test (SPT) and APT reactivity and presence
of serum IgE to extract of M. furfur and recombinant M. furfur
allergens (rMal f 1, rMal f 5, and rMal f 6) in AD patients and
healthy controls. In response to in vitro M. furfur stimulation both
PBMC proliferation and Th2 cytokine production correlated with
the APT reactions to M. furfur. Thus, these data strongly suggest a
relationship between circulating speci®c T cells with a Th2-like
cytokine pro®le and positive APT reactions.
MATERIALS AND METHODS
Subjects Forty patients, with mild±severe AD according to the clinical
criteria of Williams et al, 1994, and 16 healthy controls, were included in
the study (Table I). Exclusion criteria were eczema only on the hands,
autoimmune diseases, in¯ammatory skin diseases other than atopic
dermatitis, immune suppressive treatment, or use of systemic
corticosteroids or solarium in the previous 2 mo. On the test sites, no
topical antifungal treatment was permitted for 1 mo before the study and
no topical corticosteroid for 1 wk before. Antihistamine was withdrawn
5 d before the investigation. The healthy controls had no clinical
symptoms or history of allergy or skin diseases. Twenty-six of the 40
investigated AD patients had elevated total serum IgE (> 122 kU per
liter, ImmunoCap, Pharmacia Diagnostics AB, Uppsala, Sweden) and
positive Phadiatop (serum IgE to any of 11 common aeroallergens,
Pharmacia Diagnostics AB) together with rhinoconjunctivitis and/or
asthma. Four of the patients had total serum IgE < 122 kU per liter,
were negative in Phadiatop and had no rhinoconjunctivitis or asthma,
whereas the remaining 10 AD patients had one or two of these
conditions. The subjects gave their informed consent for the study,
which was approved by the Regional Ethics Committee of Karolinska
Institutet, Stockholm, Sweden.
Stimulating antigens Crude M. furfur extract (strain no. 42132,
American Type Culture Collection) was prepared as previously described
(Zargari et al, 1994). Recombinant M. furfur allergens (rMal f 1, rMal f 5,
and rMal f 6) and the recombinant control allergen (rAca s 13, a minor
allergen from the dust mite Acarus siro; Eriksson et al, 1999) were
produced in the Escherichia coli system as described earlier (Schmidt et al,
1997; Eriksson et al, 1999; Lindborg et al, 1999). For each allergen
(extract and various recombinants) one single batch was prepared and
used throughout the whole study in both in vitro experiments and in vivo
testing (SPT and APT). The test batches had, in the concentration of
10 mg protein per ml, a nucleic acid content of less than 60 pg per ml
(DNA dipstick, Invitrogen, San Diego, CA) and an endotoxin content of
less than 7 EU per ml (Limulus test, performed by Apoteket AB,
Stockholm, Sweden). BCA Protein Assay Reagent (Pierce Chemical
Company, Rockford, IL) was used for determining protein
concentration in the extract, whereas the protein concentrations in the
recombinant allergen preparations were estimated by spectrophotometric
absorbance at 280 nm. Protein purity was checked with sodium dodecyl
sulfate±polyacrylamide gel electrophoresis. No signi®cant changes, for
extract or recombinant proteins, was found in repeated measurement of
concentration and purity checking after the study. Phytohemagglutinin
(PHA) was purchased from Amersham Pharmacia Biotech, and tetanus
toxoid (TT) was obtained from SBL Vaccine Distribution, Stockholm,
Sweden.
In vivo tests and serum IgE to M. furfur All subjects were tested for
serum IgE, SPT, and APT reactions to the crude M. furfur extract, the
recombinant M. furfur allergens rMal f 1, rMal f 5, and rMal f 6, and the
recombinant control allergen rAca s 13. The SPT was performed
according to standard procedure (Dreborg, 1989) in a concentration of
100 mg allergen per ml and evaluated after 15 min. PBS served as
negative control and histamine dihydrochloride (10 mg per ml; ALK,
Hùrsholm, Denmark) as positive control. The reactions were graded as
mean diameter in millimeters, a reaction with mean diameter of 3 mm
or more being considered as positive. The APT was performed as
previously described (Tengvall Linder et al, 2000). Brie¯y, the allergens
or the vehicle control PBS were applied on paper discs in Finn chambers
(8 mm; Epitest Ltd Oy, Tuusula, Finland) on tape-stripped, nonlesional
skin of the back. The recombinant allergens were tested at a
concentration of 4 mg per ml and the M. furfur extract in a 2-fold serial
dilution of 5.0±0.6 mg per ml. The APT were removed after 48 h and
the skin reactions were evaluated. The test results were scored as:
0 = negative reaction; + = erythema, in®ltration, and possible papules;
++ = erythema, in®ltration, papules, and small vesicles; and
+++ = erythema, in®ltration, papules, and large vesicles (Rietschel and
Fowler, 1995; Tengvall Linder et al, 2000). For the M. furfur extract, the
highest APT score in each individual, regardless of concentration, was
used in further comparisons.
Speci®c serum IgE for M. furfur was analyzed with ImmunoCAP
``m70'' (Pharmacia Diagnostics AB, prepared from M. furfur extract
according to Zargari et al, 1994; strain no. 42132, American Type
Culture Collection). For analysis of serum IgE speci®c to the recombi-
nant M. furfur allergens rMal f 1, rMal f 5, and rMal f 6, the allergens
were immobilized on to cellulose solid phase (ImmunoCAP) by covalent
binding (MIAB, Uppsala, Sweden). The coupling concentration was
adjusted to attain a linear measurement range and a background below
0.35 kU per liter. The recombinant ImmunoCAPs were tested in the
Pharmacia CAP system according to the manufacturer's instructions.
Preparation of PBMC and culture conditions PBMC were isolated
from heparinized blood by gradient centrifugation on Ficoll-paque
(Amersham Pharmacia Biotech). As culture medium we used RPMI
Table I. Characterization of the AD patients and healthy controlsa
In vivo reactions
to M. furfur extract n
Gender
M/F
Age in years
median
(range)
Head and
neck
distribution
n R/A n
Total serum
IgEc kU per
l median
(range)
Total
serum IgE
> 122 kU
per liter
n
Phadiatopd
n of
positive
Speci®c
serum IgEe to
M. furfur n
of positive
ADb (SPT+/APT+) 12 3/9 27 (21±43) 12 8/6 2900 (59±7000) 10 10 10f
ADb (SPT+/APT±) 12 5/7 38 (24±50) 9 11/4 1110 (130±3700) 12 11 8g
ADb (SPT±/APT±) 16 9/7 38 (19±49) 10 8/8 147 (5± 1700) 8 12 0
HC 16 3/13 29 (21±54) na 0/0 21 (4±220) 1 3 0
aHC, healthy controls; M/F, male/female; R, rhinoconjunctivitis; A, asthma; na, not appropriate.
bThe AD patients are grouped according to their in vivo SPT and APT reactivity against the crude M. furfur extract.
cImmunoCAP (Pharmacia Diagnostics AB), reference range 1.6±122 kU per liter.
dPhadiatop (Pharmacia Diagnostics AB), serum IgE to any of 11 common aeroallergens.
eImmunoCAP (Pharmacia Diagnostics AB), reference range < 0.35 kU per liter.
fMedian 2.0 kU per liter, range 0.43±22.0 kU per liter.
gMedian 5.1 kU per liter, range 1.4±17.0 kU per liter.
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1640 supplemented with 25 mg gentamicin per ml, 100 IU penicillin per
ml, 100 mg streptomycin per ml, 2 mM L-glutamine (Gibco BRL, Life
Technologies Ltd, Paisley, U.K.) and 50 mM 2-mercaptoethanol (Merck,
Darmstadt, Germany). Further 10% pooled, heat-inactivated human
ABRh + serum with IgE content < 10 kU per liter, negative Phadiatop,
and no speci®c M. furfur IgE (ImmunoCAPÔ) was added. The cells
were cultured at 37°C and 6% CO2 in air.
PBMC proliferation assay Freshly isolated PBMC (2 3 105 cells in
200 ml culture medium per well) were cultured in 96-well round-
bottomed plates (Falcon, Becton Dickinson, Franklin Lakes, NJ) with or
without antigen stimulation. The proliferation after stimulation with M.
furfur extract (50, 10, 1, and 0.1 mg per ml) was measured after 3 and 7 d
incubation. The recombinant M. furfur allergens and rAca s 13 (10, 1,
and 0.1 mg per ml) were tested after 7 d incubation only, due to limited
number of cells. As proliferation controls the mitogen PHA (10 mg per
ml) was used for 3 d incubation and the protein antigen TT (10 mg per
ml) for 3 and 7 d incubation. All tests were set up in triplicate. During
the last 18 h of incubation 1 mCi [3H]thymidine (25 Ci per mmol,
Amersham Pharmacia Biotech) was added to each well and the
thymidine incorporation was determined by scintillation counting. The
results are expressed as mean cpm for triplicates and as stimulation index
(SI) calculated as mean cpm for stimulated cells divided by mean cpm for
unstimulated cells.
Analysis of cytokine-producing cells in PBMC The number of
cytokine producing cells was estimated in 35 of the individuals, from
whom suf®cient numbers of cells were obtainable, selected regardless of
their in vivo and in vitro reactivity to M. furfur. The reverse ELISPOT
assay was used on freshly prepared or frozen PBMC, mainly as described
before (Gabrielsson et al, 2001). Brie¯y, prewetted sterile Multiscreen
Immobilon-P Membrane plates (Millipore, Bedford, MA) were coated
overnight at +4°C (15 mg per ml, 100 ml per well) with anti-IL-4
monoclonal antibody (MoAb) (IL-4-I) or anti-IL-13 MoAb (IL13-I)
(MabTech AB, Stockholm, Sweden). The unbound MoAb was washed
away with PBS, followed by the culture medium, whereupon 100 ml of
PBMC (2 or 3 3 105 cells per well, prestimulated with 10 mg M. furfur
per ml, 10 mg PHA per ml, or medium alone for 4 h) was added to the
wells. The cells were incubated for 44 h at 37°C in 6% CO2, before
being washed away. Produced cytokines were detected by incubation
with 1 mg per ml of biotin-labeled anti-IL-4 (IL-4-II) or anti-IL-13 (IL-
13-II) MoAb (Mabtech AB), followed by several washes and incubation
with streptavidin±alkaline phosphatase (Mabtech AB, dilution 1/1000).
Unbound conjugate was removed with another series of washing and
®nally 100 ml of BCIP/NBT (Alkaline Phosphatase Conjugate Substrate
Kit obtained from Bio-Rad Laboratories, Hercules, CA) was added and
incubated at room temperature until dark spots emerged. The spots were
counted in a dissection microscope (340). All assays were set up in
triplicate wells and the results are presented as the mean number of
cytokine-producing cells in 105 PBMC.
Measurement of cytokines secreted into the culture media Freshly
isolated PBMC (2 3 106 cells per 2 ml culture medium) were incubated
in 48-well, ¯at-bottomed culture plates (Falcon) with or without M.
furfur extract (10 mg per ml). The culture supernatants were collected at
day 8, which was found in preliminary investigations to be optimal for
both IL-5 and IFN-g. The supernatants were centrifuged at 300 3 g to
remove the cells and kept at ±20°C until assessed for the presence of
IL-5 and IFN-g by enzyme-linked immunosorbent assay technique
according to the manufacturer's instructions (IL-5, PharMingen Research
Products, San Diego, CA; IFN-g, Mabtech AB). Brie¯y, 96-well, ¯at-
bottomed plates (Nunc, Roskilde, Denmark) were coated with the
MoAb: anti-IL-5 MoAb (TRFK5; 4 mg per ml, 50 ml per well) or anti-
IFN-g MoAb (1-D1K; 2 mg per ml, 100 ml per well) overnight at room
temperature followed by treatment with 200 ml of PBS containing 1%
bovine serum albumin (Sigma, St Louis, MO). Next, samples or
standards (100 ml) were added to the wells in duplicate followed by
addition of 1 mg per ml of biotin-labeled anti-IL-5 (JES15A10), or anti-
IFN-g (7-B6-1) MoAb. After incubation with streptavidin±alkaline
phosphatase (Mabtech AB, dilution 1/1000), the substrate (p-nitro-
phenyl-phosphatase disodium, Sigma), diluted in 1 M diethanolamine
buffer, pH 9.8 was added. The absorbance at 405 nm was measured with
an enzyme-linked immunosorbent assay plate reader (Labsystem
Multiscan, Finland). As standards, recombinant human IL-5
(PharMingen) and recombinant human IFN-g (Bender MedSystems,
Vienna, Austria) were used. The detection limit for IL-5 was 35 pg per
ml and for IFN-g 30 pg per ml.
Statistical methods Differences between the groups were analyzed
with Kruskal±Wallis ANOVA by ranks and post-hoc comparisons were
made with the Mann±Whitney U test. Friedman ANOVA was used for
comparison of responses with the different recombinant allergens within
the groups and post-hoc comparisons were made with the Wilcoxon
matched pair test. Correction for multiple comparisons was made with
the Bonferroni method. All tests followed a two-sided alternative
hypothesis. Correlations were calculated using Spearman rank correlation
analysis. A p < 0.05 was considered as statistically signi®cant.
RESULTS
In vivo response and speci®c serum IgE Twenty-four of the
AD patients (60%) responded with positive SPT reaction to M.
furfur extract and 50% of these also responded with a positive APT
reaction to the M. furfur extract (Table I). Fewer AD patients
responded in vivo to the recombinant M. furfur allergens than to the
extract (Tables II and III). The pattern of in vivo SPT/APT
response to rMal f 5 was most similar to the in vivo response to M.
furfur extract (Table II). As expected, only a few individuals
responded with in vivo reactions to the irrelevant control allergen
rAca s 13 (Table II). None of the healthy controls reacted with a
positive SPT or APT reaction to M. furfur extract or any of the
recombinant allergens.
The SPT for M. furfur extract seemed to be more sensitive than
ImmunoCap as all patients who had measurable serum IgE to the
extract also responded with a positive SPT, and an additional six
patients who had M. furfur-speci®c serum IgE below the detection
limit had a positive SPT, two of them together with a positive APT
(Table I). The two SPT+/APT+ AD patients that were negative in
ImmunoCap for M. furfur-speci®c IgE were also negative in
Phadiatop and had relatively low total serum IgE levels (98 and
160 kU per liter, respectively). These patients stated not to have
had symptoms of rhinoconjunctivitis or asthma.
Table II. Comparison between in vivo reactivity to M. furfur extract and the recombinant allergens in the AD patients
M. furfur extracta n
rMal f 1b rMal f 5b rMal f 6b rAca s 13b
SPT+/
APT+
SPT+/
APT±
SPT±/
APT+
SPT+/
APT+
SPT+/
APT±
SPT±/
APT+
SPT+/
APT+
SPT+/
APT±
SPT±/
APT+
SPT+/
APT+
SPT+/
APT±
SPT±/
APT+
ADa 12 0 1 2 6 1 0 2 5 1 0 1 0
(SPT+/APT+)
ADa 12 0 4 0 1 6 0 1 4 1 1 0 0
(SPT+/APT±)
ADa 16 0 0 0 0 0 0 0 2 0 0 0 0
(SPT±/APT±)
Total AD 40 0 5 2 7 7 0 3 11 2 1 1 0
aThe AD patients are grouped according to their in vivo reactivity against the crude M. furfur extract.
bNumber of individuals positive in SPT and/or APT against rMal f 1, rMal f 5, rMal f 6 or rAca s 13, respectively.
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A statistically signi®cant correlation was found between M.
furfur-speci®c serum IgE and total serum IgE (rs = 0.70, p < 0.001)
but not between M. furfur-speci®c serum IgE and the SPT reaction
(rs = 0.19, p = 0.20) in the 24 AD patients with positive SPT
reaction to M. furfur extract. In this group no correlations were
found between the APT reaction to M. furfur extract and M. furfur-
speci®c serum IgE or the SPT reaction to M. furfur (rs = 0.24,
p = 0.27 and rs = 0.31, p = 0.14, respectively); however, in the
whole group of AD patients (n = 40), there were correlations
between the APT reaction to M. furfur extract and M. furfur-speci®c
serum IgE (rs = 0.52, p < 0.001) or SPT to M. furfur (rs = 0.58,
p < 0.001).
In contrast to the results with the M. furfur extract, a few
individuals with speci®c serum IgE for any of the recombinant
allergens had negative SPT reaction to the same allergen
(Table III). Speci®c serum IgE for M. furfur extract or any of the
recombinant M. furfur allergens was not found in any of the healthy
controls.
PBMC response to M. furfur extract correlated with APT
reaction The general pattern, at both time points and at all
concentrations investigated, was a signi®cantly higher SI to M.
furfur extract in the AD patients with positive SPT to M. furfur
extract (p < 0.01 compared with healthy controls and p < 0.05
compared with the SPT± patients) The SPT± AD patients and the
healthy controls showed equally low proliferation (data not shown).
The AD patients with positive SPT to M. furfur extract were further
subdivided according to their APT reaction to the extract, and
median SI was six times higher in the APT+ group than in the
SPT+/APT± patients after 3 d stimulation with M. furfur extract
(Fig 1). In the AD patients with positive SPT reaction to M. furfur
extract, a signi®cant correlation was found between SI and APT
reaction to the extract (Fig 2).
Table III Comparison between in vivo reactivity and speci®c serum IgE to the recombinant M. furfur allergens
rMal f 1 rMal f 5 rMal f 6
S nb
negative
< 0.35 kU
per literc
n
class
1±2c
n
class
3c
n
class
4±5c
n S nb
negative
< 0.35 kU
per literc
n
class
1±2c
n
class
3c
n
class
4±5c
n S nb
negative
< 0.35 kU
per literc
n
class
1±2c
n
class
3c
n
class
4±5c
n
ADa 0 0 0 0 0 7 0 0 4 3 3 2 0 0 1
(SPT+/APT+)
ADa 5 0 0 3 2 7 2 3 1 1 11 1 0 3 7
(SPT+/APT±)
ADa 2 2 0 0 0 0 0 0 0 0 2 1 1 0 0
(SPT±/APT+)
ADa 33 32 0 0 1 26 24 2 0 0 24 24 0 0 0
(SPT±/APT±)
aThe AD patients are divided according to their in vivo reactivity to rMal f 1, rMal f 5, or rMal f 6, respectively.
bTotal number of individuals with the stated pattern of in vivo reactivity to rMal f 1, rMal f 5, or rMal f 6, respectively.
cNumber of individuals with speci®c serum IgE (ImmunoCAP) to rMal f 1, rMal f 5, or rMal f 6, respectively, divided according to the RAST-class system; class 1±
2 = 0.35±3.5 kU per liter, class 3 = > 3.5±17.5 kU per liter, class 4±5 = > 17.5±100.0 kU per liter. < 0.35 kU per liter was considered as negative.
Figure 1. Elevated PBMC proliferation to M. furfur extract in the
in vivo M. furfur reactive AD patients. PBMC proliferation to M.
furfur extract in healthy controls (HC) and AD patients, grouped
according to their in vivo reactivity to the M. furfur extract. The
proliferation was measured as [3H]thymidine incorporation in triplicate
cultures, after 3 d stimulation with M. furfur extract (10 mg per ml). The
result are presented as SI calculated as counts per minute for stimulated
cells divided by cpm for unstimulated cells. Median for unstimulated cells
was 406 cpm, range 176±1690 cpm (n = 56). Data are analyzed with
Kruskal±Wallis ANOVA by ranks (p < 0.001), post-hoc comparisons made
with the Mann±Whitney U test corrected for multiple comparisons using
the Bonferroni method. Arrows indicate statistically signi®cant differences
in pairs.
Figure 2. Positive correlation between SI and APT reaction to
M. furfur extract. The correlation (rs = 0.62, p < 0.01) was calculated
between SI for M. furfur extract (10 mg per ml) and APT reaction to M.
furfur extract in AD patients with positive SPT to the extract (n = 24).
The proliferation was measured as [3H]thymidine incorporation in
triplicate cultures, after 3 d stimulation with 10 mg per ml M. furfur
extract. The SI was calculated as counts per minute for stimulated cells
divided by cpm for unstimulated cells. The median for unstimulated cells
was 399 cpm, range 190±1690 cpm (n = 24). The APT was performed
in a 2-fold serial dilution of 5.0±0.6 mg per ml M. furfur extract. The
APT reactions were evaluated after 48 h and scored as 0 to +++ (see
Materials and Methods). The highest scores, regardless of concentration,
are presented.
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PBMC proliferation to M. furfur extract was measured on both
days 3 and 7 and the same pattern of differences between the groups
was found at both time points. Prolonged incubation time only
resulted in larger variations, both within triplicates and between
individuals within the groups. This con®rms the relevance of
measurement of PBMC proliferation to M. furfur extract on day 3,
the time-point used in earlier studies (Tengvall Linder et al, 1996,
1998, 2000 Johansson et al, 1999).
No differences between the three patient groups and the healthy
controls were found in cpm for the mitogen PHA after 3 d
stimulation (median 183,029 cpm, range 87,208±389,161, n = 56),
or in SI for the control antigen TT on day 3 (median 6.2, range
1.3±47, n = 56) or day 7 (median 12.1, range 0.4±192, n = 56).
PBMC response to the recombinant M. furfur allergens was
not connected to the in vivo response When the PBMC
proliferation in response to the recombinant M. furfur allergens was
compared with that to the recombinant control allergen rAca s 13
(Fig 3), a signi®cantly higher response to rMal f 1 was found in
both healthy controls and AD patients with or without SPT+ to M.
furfur extract (p < 0.01, p < 0.001, p < 0.05, respectively). For
Figure 3. PBMC proliferation to the recombinant M. furfur
allergens (rMal f 1, rMal f 5 and rMal f 6) compared with the
control allergen rAca s 13. PBMC proliferation was measured as
[3H]thymidine incorporation in triplicate cultures, after 7 d stimulation
with 10 mg per ml of the recombinant allergens, in (A) AD patients
SPT+ to M. furfur extract, (B) AD patients SPT± to M. furfur extract, and
in (C) healthy controls. The result are presented as SI calculated as
counts per minute for stimulated cells divided by cpm for unstimulated
cells. The median for unstimulated cells was 1464 cpm, range 272±
13,886 cpm (n = 56). Data are analyzed with Friedman ANOVA by ranks
(p < 0.001 for all three groups of individuals), post-hoc comparisons made
with the Wilcoxon matched pairs test corrected for multiple comparisons
using the Bonferroni method. Statistically signi®cant higher SI than for
Aca s 13 are indicated with **p < 0.01 and *p < 0.05.
Figure 4. Elevated number of IL-4- and IL-13-producing cells in
response to M. furfur extract in in vivo reactive AD patients. The
frequency of (A) IL-4-producing cells and (B) IL-13-producing cells in
response to in vitro stimulation with M. furfur extract (10 mg per ml) was
measured with the ELISPOT method in triplicate measurements and
presented as mean number of cytokine-producing cells in 105 PBMC.
The results are presented in healthy controls (HC) and AD patients,
grouped according to their in vivo reactivity to the M. furfur extract. IL-
4- and IL-13-producing cells in unstimulated PBMC were always fewer
than 2 in 105 PBMC. Data are analyzed with the Kruskal±Wallis ANOVA
by ranks (p < 0.001 for IL-4 and IL-13, respectively), post-hoc
comparisons made with the Mann±Whitney U test corrected for
multiple comparisons using the Bonferroni method. Horizontal bars
indicate median values and arrows indicate statistically signi®cant
differences.
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rMal f 6, higher proliferation was found in AD patients with or
without SPT+ to M. furfur extract but not in the healthy controls
(p < 0.05, p < 0.05, p = 0.68, respectively). rMal f 5 gave no
signi®cant PBMC stimulation in any of the groups (Fig 3). The
PBMC reactivity to the control allergen rAca s 13 was generally
low (median SI 1.3) and only ®ve individuals showed a SI of more
than 3.2.
In contrast to the M. furfur extract, no correlation between
PBMC proliferation in response to the recombinant allergens and
in vivo response was seen for any of the recombinant M. furfur
allergens. No signi®cant differences in PBMC proliferation for any
of the recombinant allergens were observed between the groups of
AD patients, either when the patients were subdivided according to
in vivo response to the extract or when subdivided by in vivo
response to the recombinant allergen being tested (data not shown);
however, in the proliferative response to rMal f 6 a signi®cant
difference was found between the healthy controls and the whole
AD group (p < 0.001). The higher proliferative response to Mal f 6
persisted in all AD groups, compared with the healthy controls,
when the AD patients were further subdivided according to in vivo
reactivity to rMal f 6 (p < 0.05) or M. furfur extract (p < 0.05),
although there were no differences between the AD groups (data
not shown).
Th2 cytokine production in response to M. furfur extract
correlated with SI and APT reactions The AD patients with
SPT+/APT+ to the extract responded with signi®cantly higher
numbers of IL-4 producing cells (p < 0.05) than the other groups
of AD patients and the healthy controls (Fig 4A). Also the SPT+/
APT± group responded with signi®cantly higher numbers of IL-4-
producing cells (p < 0.05) than the healthy controls. In addition,
the SPT+/APT+ AD patients responded with higher numbers of
IL-13 producing cells (p < 0.01) than the SPT±/APT± group and
the healthy controls (Fig 4B). The response to PHA analyzed in
parallel was > 90 IL-4 and > 150 IL-13 producing cells in 105
PBMC.
A signi®cantly higher IL-5 production was found in the SPT+/
APT+ AD patients than in the other groups of AD patients and
healthy controls (p < 0.01, Fig 5A), where the IL-5 production
was below the detection limit (35 ng per ml) for several individuals.
For the unstimulated control PBMC cultures, IL-5 levels above the
detection limit were found in three individuals only (38±44 ng per
ml). IFN-g production was detected in both M. furfur stimulated
and unstimulated cell cultures from all individuals; however, no
signi®cant differences were found between the healthy controls and
AD groups either in unstimulated (data not shown) or in M. furfur-
stimulated cell cultures (Fig 5B). In the M. furfur SPT+ AD patients
the degree of APT reaction, PBMC proliferation expressed as SI
and Th2 cytokine production in response to M. furfur all correlated
with each other (Table IV).
DISCUSSION
This study strongly suggests a relationship between circulating
allergen-speci®c T cells and positive APT reactions. We have for
the ®rst time shown signi®cantly higher PBMC proliferation to an
allergen (M. furfur) in AD patients with positive APT reaction to
this allergen, than in AD patients with speci®c IgE but negative
APT. Although the SPT+/APT± patients responded with signi®-
cantly higher PBMC proliferation to M. furfur than healthy
individuals did, considerably higher proliferation was found in
the patients also positive in the APT reaction. The high PBMC
proliferation in the APT+ patients correlated with a high number of
Th2 cytokine-producing cells, further supporting their ability to
contribute to the eczematous reaction.
Association between speci®c serum IgE and positive APT
reactions has previously been reported (Langeveld-Wildschut et al,
1996, 2000; Wistokat-WuÈl®ng et al, 1999; Tengvall Linder et al,
2000). Our study supports this association, as all patients with
positive APT reaction to M. furfur extract also had a positive SPT
reaction and all but two had speci®c serum IgE to M. furfur extract.
Membrane-bound IgE improves the allergen-presenting capacity of
Langerhans cells (Mudde et al, 1990) and monocytes (Maurer et al,
1995). In a recently published study Langeveld-Wildschut et al
(2000) suggest that a positive APT reaction requires the presence of
epidermal IgE+ Langerhans cells in clinically noninvolved skin, but
that other as yet unknown, factors are also involved. Such a factor
could be the presence of allergen-speci®c Th2 cells, which can
release cytokines that promote an in¯ammatory reaction; however,
in their study Langeveld-Wildschut et al (2000) could establish
house dust mite allergen-speci®c T cell lines from uninvolved skin
from only half of the patients with positive APT reaction. If this
re¯ects the true situation in the skin, there may also be an early
recruitment of allergen-speci®c T cells from the circulation.
Although we found a clear association between the presence of
speci®c IgE and positive APT reaction to M. furfur, the Th2-like
PBMC response to M. furfur showed stronger correlation with the
APT reaction than did the speci®c IgE levels or SPT reaction. This
supports the hypothesis that the Th2-like T cell response is one of
the crucial factors for allergen-speci®c eczema reactions in AD.
The fact that we observed a strong PBMC proliferation to M.
furfur extract only in sensitized AD patients speaks against the
possibility of a mitogenic effect. The antigenicity in the extract in
combination with preactivated allergen-speci®c T cells in the
Figure 5. Elevated IL-5 but unchanged IFN-g production in
response to M. furfur extract in in vivo reactive AD patients. In
vitro IL-5 (A) and IFN-g (B) production from PBMC (2 3 106 cells per
ml), in response to stimulation with M. furfur extract (10 mg per ml), was
measured with enzyme-linked immunosorbent assay as secretion into the
cell culture medium on day 8. The results are presented as mean of
duplicates. Data are analyzed with the Kruskal±Wallis ANOVA by ranks
(p < 0.001 for IL-5 and p = 0.390 for IFN-g), post-hoc comparisons
made with the Mann±Whitney U test corrected for multiple
comparisons using the Bonferroni method. Horizontal bars indicate
median values and arrows indicate statistically signi®cant differences.
VOL. 118, NO. 6 JUNE 2002 APT, SPT, AND IN VITRO REACTIONS TO M. FURFUR 1049
sensitized individuals is a more likely explanation of the early
proliferation. Wistokat-WuÈl®ng et al (1999) also showed signi®-
cantly higher PBMC proliferation in AD patients with positive
APT reactions against cat, grass pollen, and house dust mite
allergens. A weakness in their study design was that the APT+ AD
patients were compared with a heterogeneous group of AD
patients, without subgrouping for speci®c IgE to the allergen in
question. Nevertheless, both the study by Wistokat-WuÈl®ng et al
(1999) and our data support an association between T cell-mediated
speci®c immune response and the APT reaction to an allergen.
The difference between the antigen-stimulating capacity of M.
furfur extract and the recombinant M. furfur allergens may be due to
several things. First, a few different allergens, randomly selected
from several Mal f allergens and used one by one, can only be
expected to mimic partly the extract. Another important difference
between the crude extract and the pure recombinant allergens may
be that they have a different ability to stimulate antigen-presenting
cells. Full extracts of allergenic substances contain not just the actual
allergens, but also substances that can probably serve as adjuvants
and enhance antigen-speci®c reactions. This may also explain the
lack of concordance between in vitro PBMC and in vivo APT
reactions to the recombinant allergens. In this study it was found
that all three recombinant M. furfur allergens tested, rMal f 1, rMal f
5, and rMal f 6, could cause positive SPT and APT reactions in AD
patients. Recombinant allergens may in the future become useful
diagnostic tools for AD, in that a mix of relevant recombinant
allergens will provide a standardized and more stable preparation
than crude allergen extracts; however, at present, the M. furfur
extract still provides the best tool.
The Th2-like cytokine production in response to M. furfur in
AD patients agrees with previous ®ndings (KroÈger et al, 1995;
Tengvall Linder et al, 1996, 1998; Savolainen et al, 2001). This
is, to our knowledge, the ®rst time the ELISPOT method has
been used for detecting allergen-induced cytokine production in
AD patients, although it has been used in investigations of
respiratory atopic manifestations (Gabrielsson et al, 2001).
Measurement of the total amount of produced cytokine gives
general information, but the cytokine may be secreted by only
a few highly productive cells, or the levels may be falsely low
due to consumption within the cell culture. The ELISPOT
method, on the other hand, makes it possible to estimate the
frequency of cytokine-producing cells in a population. We
found a high frequency of IL-4- and IL-13-producing cells,
both cytokines supporting IgE production (Leung, 2000), in
response to M. furfur stimulation in the M. furfur APT+ AD
patients. In addition, those patients produced large amounts of
IL-5, not detected in most individuals in the other groups. IL-5
promotes growth and differentiation of eosinophils (Leung,
2000), one of the early skin-in®ltrating cells in the APT
reaction (Bruynzeel-Koomen et al, 1988; Tengvall Linder et al,
2000). The IFN-g production in response to M. furfur was not
elevated in our AD patients or in the healthy controls. In the
healthy controls and in the M. furfur SPT± AD patients this
accords with the low proliferative response to M. furfur.
Conversely, this lack of elevated IFN-g production in the M.
furfur SPT+ AD patients with elevated proliferative PBMC
response to M. furfur is likely to be due to a highly Th2-
skewed response. In vitro studies of antigen uptake and
presentation by human dendritic cells have shown that M.
furfur uptake directs the dendritic cells to promote a Th2-like
response (Buentke et al, 2001). The source of the elevated IFN-
g levels seen in chronic AD lesions (Grewe et al, 1994; Hamid
et al, 1994) might not be those allergen-stimulated speci®c T
cells but, rather, nonspeci®c T cells recruited to the AD lesion
(Leung, 2000).
Speci®c serum IgE to M. furfur are preferentially found in AD
patients with high total serum IgE levels and other signs of atopic
manifestations such as positive Phadiatop and allergic asthma and/
or rhinoconjunctivitis (Wessels et al, 1991; Nordvall et al, 1992).
Nevertheless, in our rather small group of M. furfur APT+ AD
patients we found two patients without those criteria and also
without measurable levels of speci®c serum IgE to M. furfur. We
still do not expect their patch test reactions to be Th1-dominated
contact dermatitis reactions, as both patients showed local speci®c
IgE reactivity in the M. furfur SPT reaction. These patients also had
a clearly elevated Th2-like proliferative PBMC response to M.
furfur. Thus, the possibility of a worsened AD eczema due to M.
furfur sensitization should not be forgotten in the subgroup of adult
AD patients without atopic symptoms other than AD.
Using M. furfur extract we have shown a clear association
between positive APT reactions and elevated PBMC proliferation
accompanied by Th2 cytokine production in response to allergen
stimulation. These data strongly suggest a relationship between
circulating allergen-speci®c Th2 cells and positive APT reactions.
Those T cells may either provide a pool for rapid recruitment to
the skin, or re¯ect spillover of cells harbored in AD skin, or both,
Table IV. Correlations between in vivo and in vitro test results in the M. furfur SPT positive AD patients
APT to M. furfur
(0 ± + + +)
n = 24a
SI to M. furfur
SI to M. furfur 0.62b **c (3 d, 10 mg per ml)
(3 d, 10 mg per ml) n = 24
n = 24
M. furfur 0.76 *** 0.80 *** M. furfur induced
induced IL-4 IL-4 producing
producing cells n = 18
cells n = 18 M. furfur induced
M. furfur induced 0.70 ** 0.81 *** 0.95 *** IL-13 producing
IL-13 producing cells n = 16
cells n = 16
M. furfur induced IL-5 0.75 *** 0.58 ** 0.62 *** 0.57 *
production n = 24
aCorrelations were calculated in the whole group of M. furfur SPT+ AD patients (n = 24) for all parameters, but IL-4 and IL-13-producing cells (due to lack of cells from
six or eight individuals, respectively), as indicated in the table.
bCorrelations were calculated using Spearman rank correlation analysis and rs-values obtained are given in the table.
c***p < 0.001,
**p < 0.01,
*p < 0.05.
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and might together with epidermal IgE+ Langerhans cells be
essential for the APT reaction.
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